To view all full-text abstracts and accompayning presentations, if submitted, visit the Digestive Disease Week® (DDW) 2020 ePosters and ePapers site.
Abstract Mo1498: High visitor activation one year after ultrasound-based population screening for increased liver stiffness at the 2018 Minnesota State Fair
Piet de Groen, MD, professor of medicine, University of Minnesota, Twin Cities
Fatty liver disease affects more than 30% of U.S. adults and can cause cirrhosis; yet, screening for fatty liver disease is not advised. This study conducted population screening for early fatty liver disease at the Minnesota State Fair over five days in 2018 to determine whether screening would result in consultation with a health care provider and/or lifestyle modifications. At the fair, 460 visitors completed the tablet-based questionnaire and 139 met inclusion criteria for screening. Of those, 132 people completed the screening behind privacy screens and 92 of those screened had at least one indication of early fatty liver. One year after screening, 72% had consulted a physician, were started on treatment and/or had made changes to their lifestyle.
Abstract Mo1560: Cannabis use is associated with reduced 30-day readmission among hospitalized patients with irritable bowel syndrome: A nationwide analysis
Catherine Choi, MD, resident physician, PGY-2, department of medicine, Rutgers New Jersey Medical School, Newark
This retrospective cohort study utilizing the 2016 Nationwide Readmissions Database hypothesized that cannabis use is associated with better control of irritable bowel syndrome (IBS). A total of 6,798 patients with the diagnosis of IBS were identified, 357 of whom used cannabis. Researchers found that cannabis use is associated with reduced 30-day readmission rates among patients with IBS (8.1 percent) compared to non-users (12.7 percent) after adjusting for age, sex, income, insurance, status, hospital bed-size and teaching status. Cannabis use was also associated with shorter length of stay and lower hospitalization charges.
Abstract 815: Impact of parental illness and injury on pediatric disorders of gut-brain interaction
Patrick Short, MD, pediatric gastroenterology, hepatology and nutrition fellow, National Capital Consortium, Uniformed Services University of the Health Sciences, Bethesda, MD
Researchers conducted a self-controlled case series using Military Health System Data to evaluate whether parental injuries and illnesses are associated with increased health care and prescription use for disorders of gut-brain interaction among their children. Study included 442,651 children ages 3-16 with a military parent who was ill or injured between 2004 and 2014. Researchers identified outpatient visits for irritable bowel syndrome (IBS), abdominal pain, constipation and fecal incontinence (FI) in the two years before and after parental injury. They found that parental injuries and illnesses are associated with increased health care utilization for pain-related disorders of gut-brain interaction, as well as increased antispasmodic prescriptions. Parental brain injury has the highest association with increased abdominal pain and antispasmodics prescription. Parental injuries and illnesses were associated with defecation-related disorders only in children under six.
Abstract 832: Effect of moderate alcohol consumption on obesity-induced stimulation of villus cell brush border membrane Na-glutamine co-transport in the small intestine
Soudamani Singh, PhD, assistant professor, department of clinical and translational sciences, Marshall University Joan C. Edwards School of Medicine, Huntington, WV
Researchers set out to understand a mechanism that can explain why moderate alcohol consumption is linked to a decreased risk of obesity. The authors looked at whether alcohol prevents the absorption of glutamine in the gut of lean and obese rats. Researchers inserted alcohol or water directly into the stomachs of both the lean and obese rats and then analyzed the uptake of glutamine in the intestines of each group of rats. Alcohol consumption impacted glutamine absorption differently in the lean and obese rats. The authors conclude their study raises the possible therapeutic utility of moderate alcohol to treat obesity.
Abstract 791: Trends of sleeve gastrectomy and post-operative weight loss pharmacotherapy over 10 years: A large database study
Abbinaya Elangovan, MD, resident, department of medicine-pediatrics, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH
This retrospective review of electronic health records data of 11.2 million adults with obesity across 26 health networks in the U.S. identified 25,540 adults with morbid obesity who had undergone sleeve gastrectomy from 2010 to 2019. Pharmacotherapy was prescribed to 5.6 percent of the patients, with the trend ranging from 2.9% to 3.4% in the last five years. Authors conclude postoperative pharmacotherapy in patients with sleeve gastrectomy is underutilized, despite evidence supporting their benefit as adjuvant therapy after bariatric surgery.
Abstract Mo2010: Impact of bariatric surgery on patients with advanced heart failure supported by left ventricular assist devices: A systematic review and meta-analysis
Praneet Wander, MD, gastroenterology fellow, NorthShore University HealthSystem, Evanston, IL
This systematic review and meta-analysis of published data assessed whether patients with a body mass index (BMI) of greater than 35 with advanced heart failure supported with left ventricular assist devices (LVADs) could become eligible for heart transplantation following bariatric surgery. Typically, a person with end-stage heart failure must have a BMI of less than 35 to be eligible for heart transplantation. However, weight loss through diet and exercise is usually difficult for these patients and most bariatric surgeons find it uncomfortable to perform surgery on heart failure patients because of the high risk of complications. This research showed that bariatric surgery is an important treatment option for patients with advanced heart failure supported with LVADs, allowing them to become eligible for heart transplantation by achieving their target BMI.
